Jones Financial Companies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jones Financial Companies’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,822	Closed	-$504K	–	4200
2025 Q1	$504K	Sell	3,822 -2,768	-42%	-$345K	﹤0.01%	1123
2024 Q4	$550K	Buy	6,590 +2,750	+72%	+$226K	﹤0.01%	960
2024 Q3	$281K	Buy	+3,840	New	+$289K	﹤0.01%	1023

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jones Financial Companies's ITCI Position: Q2 2025 in Review

Jones Financial Companies sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,822 shares — an estimated $504K sold.

Jones Financial Companies first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $550K in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Jones Financial Companies reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Jones Financial Companies sold 3,822 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $504K.
Jones Financial Companies first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
Jones Financial Companies's Intra-Cellular Therapies Inc. position peaked at $550K in Q4 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Jones Financial Companies's 13F filing for Q2 2025, filed 13 Aug 2025.